A venture capital firm based in the Eastern United States invests broadly in the life science sector, and considers investment opportunities globally. The firm is likely to make 4-6 allocations in the next 6 months. Allocations typically vary from $250,000 to $5 million, in the form of equity or convertible debt. Allocations are typically made at the venture stage of development, but may be made in seed rounds if a company already has proof of their product’s efficacy.
The firm invests broadly into therapeutic, medical device and healthcare IT sectors. The firm is not restricted by development phase or indication, but does require that there be evidence of a product’s efficacy prior to investment. Rather than focusing on specific technologies or indications, the firm is interested in opportunities that display a high level of innovation and a strong market possibility; this typically leads the fund not to invest in therapeutics for indications such as Alzheimer’s disease that have proven to be difficult to bring to market.
The firm seeks to invest in strong management teams that have considerable industry experience and an understanding of entrepreneurship. It is preferred that a company is developing a product that represents the first commercial opportunity in a particular area.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment